2. Signaling Pathways
  3. Immunology/Inflammation
  4. TREM receptor
  5. TREM receptor Inhibitor

TREM receptor Inhibitor

TREM receptor Isoform Comparison

TREM receptor Inhibitors (15):

Cat. No. Product Name Effect Purity
  • HY-10227
    Bortezomib
    		Inhibitor 99.97%
    Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
  • HY-P10136
    IA9
    		Inhibitor
    IA9 (human TREM-2 182-190) is a potent, CNS-penetrant TREM-2 inhibitor. IA9 can diminish the release of proinflammatory cytokines and suppress joint inflammation and damage in a Collagen (HY-P5003)-induced arthritis (CIA) mouse model. IA9 can be used for neuroinflammation PET imaging. IA9 can be used for Rheumatoid arthritis (RA) and neuroinflammation research.
  • HY-157122
    VJDT
    		Inhibitor 99.68%
    VJDT is a TREM1 inhibitor that can effectively block TREM1 signaling. VJDT inhibits tumor cell proliferation and migration and induces cell cycle arrest. VJDT has immunomodulatory and antitumor activities, and can be used for the research of tumors such as melanoma.
  • HY-P992118
    Lifonebart
    		Inhibitor
    Lifonebart is a humanized monoclonal antibody targeting TREM2 (triggering receptor expressed on myeloid cells 2). The antibody isotype of Lifonebart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P10136A
    IA9 TFA
    		Inhibitor 98.90%
    IA9 TFA (human TREM-2 182-190 TFA) is a potent, CNS-penetrant TREM-2 inhibitor. IA9 TFA can diminish the release of proinflammatory cytokines and suppress joint inflammation and damage in a Collagen (HY-P5003)-induced arthritis (CIA) mouse model. IA9 TFA can be used for neuroinflammation PET imaging. IA9 TFA can be used for Rheumatoid arthritis (RA) and neuroinflammation research.
  • HY-10227R
    Bortezomib (Standard)
    		Inhibitor
    Bortezomib (Standard) is the analytical standard of Bortezomib. This product is intended for research and analytical applications. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
  • HY-P10086
    TREM-1 inhibitory peptide GF9
    		Inhibitor 99.41%
    TREM-1 inhibitory peptide GF9 (Human TREM-1 (213-221)) is a TREM-1 inhibitor. TREM-1 inhibitory peptide GF9 blocks the TREM-1 signaling pathway via a ligand-independent mechanism, spontaneously inserts into the cell membrane to dissociate TREM-1 from DAP-12, and functions through the Signaling Chain Homooligomerization (SCHOOL) model. TREM-1 inhibitory peptide GF9 reduces the levels of TNFα, IL-1β, IL-6, and M-CSF. TREM-1 inhibitory peptide GF9 inhibits tumor growth, prolongs the survival of mice with pancreatic cancer models, ameliorates collagen-induced arthritis, and exerts protective effects on bone and cartilage simultaneously. TREM-1 inhibitory peptide GF9 can be used in research related to arthritis, pancreatic cancer, retinopathy, alcoholic liver disease, and liver cancer.
  • HY-174378
    TREM2 agonist-4
    		Inhibitor 99.81%
    TREM2 agonist-4 (Compound 4a) is a TREM2 agonist with a Kd value of 45.9 μM. TREM2 agonist-4 can activate downstream signaling pathways of TREM2 and enhance the phagocytic function of microglia. TREM2 agonist-4 can be used in the research of neurodegenerative diseases such as Alzheimer's disease.
  • HY-P991621
    EOS006215
    		Inhibitor 98.47%
    EOS006215 (EOS-215) is a humanized monoclonal antibody targeting TREM-2. EOS006215 competes with TREM2 ligands, prevents TREM2 multimerization, and blocks downstream signaling. EOS006215 inhibits efferocytosis, reprograms transcriptomic profiles of monocyte-derived macrophages, alters metabolism and immune response genes, and increases pro-inflammatory marker secretion. EOS006215 reduces metastasis burden, delays tumor growth, and reprograms the tumor microenvironment to overcome anti-PD-1 resistance. EOS006215 can be used for the research of triple negative breast cancer and colorectal cancer.
  • HY-P11077
    LR-17
    		Inhibitor
    LR-17 (TLT-1 (94-110)), a 17-aa peptide, is a TREM-1 inhibitor. LR-17 shows anti-inflammatory effects that can reduce the secretion of pro-inflammatory cytokines induced by Lipopolysaccharides (HY-D1056) (LPS). LR-17 can be used for the study of sepsis.
  • HY-10227S
    Bortezomib-d8
    		Inhibitor 98.0%
    Bortezomib-d8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
  • HY-P991174
    Anti-TREM2 Antibody (AL2p-58)
    		Inhibitor
    Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody targeting TREM2. Anti-TREM2 Antibody (AL2p-58) can be used for the research of neuroinflammation. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P991754
    Anti-Mouse TREM2 Antibody (178)
    		Inhibitor 98.92%
    Anti-Mouse TREM2 Antibody (178) reacts with mouse TREM-2 that inhibits TREM-2 both in vivo and in vitro. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679).
  • HY-P10938
    LP17 (human)
    		Inhibitor
    LP17 (human) is a TREM1 antagonist peptide with anti-inflammatory and anti-cancer effects.
  • HY-10227G
    Bortezomib (GMP)
    		Inhibitor
    Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).